AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01125371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized brief alcohol intervention + IVR booster calls
Description: 1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
Study NCT01125371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized brief alcohol intervention
Description: Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
Study NCT01125371 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
Study NCT02194348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses
Study NCT02194348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04446546 — intervention group
Intervention type: PROCEDURE
Intervention: Vascular access by pass using a cold stored venous allograft
Description: Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
Study NCT02458820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA EEG
Description: Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
Study NCT00649272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Extended-release tablets, 15 mg
Description: 15mg, single dose fasting
Study NCT03667833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder brace
Description: Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 IV w 13,15,17,19
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 IV w 13,15,17,19
Study NCT00225173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m2 PO qod w 1-10, taper
Study NCT03818828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
Study NCT03818828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profore Compression Therapy
Description: Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
Study NCT03818828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cadexomer Iodine dressing
Description: During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
Study NCT02172573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bromocriptine
Study NCT04022226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Induction agent that suppresses infra-slow waves
Study NCT04138654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat product
Description: 300 grams per day during 2 weeks
Study NCT04138654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White meat wash-out
Description: 300 grams per day during 2 weeks
Study NCT04138654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed meat products enriched with natural compounds
Description: 300 grams per day during 2 weeks
Study NCT04138654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds
Description: 3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
Study NCT02384889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine
Description: Active Therapy with DFMO
Study NCT02384889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparitor
Study NCT04022226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Induction agent that does not suppress infra-slow waves
Study NCT02694510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light-protection of TPN solutions
Description: TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered SC
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Administered SC
Study NCT00634725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00634725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00634725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT00634725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00634725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT00634725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00634725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03716778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric rehabilitation sessions
Description: ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.
Study NCT03716778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric rehabilitation sessions
Description: ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode.
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demeclocycline
Description: Administered orally
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demeclocycline
Description: Administered orally
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Administered orally
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Administered orally
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Supplement
Description: Administered orally
Study NCT01609712 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency Kyphoplasty
Description: Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved.
Study NCT04274231 — intervention group
Intervention type: GENETIC
Intervention: different effection
Description: Analysis of the reasons for treatment
Study NCT00699387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
Study NCT01604577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interactive educational intervention
Description: Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered daily by mouth for 12 weeks
Study NCT01753856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Description: Administered orally
Study NCT02806336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi Modal Balance Training
Description: Group balance class, obstacle course, strengthening exercises
Study NCT02806336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi Modal Balance Training
Description: Group balance class, obstacle course, strengthening exercises
Study NCT02806336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Nutritional counseling to achieve 500 kcal standard hypocaloric diet
Study NCT00152477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles.
Study NCT00152477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
Study NCT00152477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 10mg/kg
Description: CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Study NCT00152477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP791 20mg/kg
Description: CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Study NCT01420692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
Study NCT01420692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
Study NCT02876458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immediate coronary angiogram
Description: An immediate coronary angiogram will be performed
Study NCT02876458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed coronary angiogram
Description: A delayed coronary angiogram (between 48 to 96 hours) will be performed
Study NCT02160665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.05%
Description: Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
Study NCT02160665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of Test product (G \& W Laboratories, Inc.)
Study NCT02160665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reference: Tazorac Cream, 0.05%
Description: Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
Study NCT00434447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00610350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: 24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
Study NCT00610350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
Study NCT00441142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LY2484595
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks
Study NCT01105975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Statins
Description: Administered daily by mouth for 12 weeks
Study NCT02824198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine (5 dose formulation)
Description: 0.5 mL, Subcutaneous
Study NCT02824198 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, NaCl 0.9%
Description: 0.5 mL, Subcutaneous
Study NCT00018096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS endotoxin, saline, HDM
Description: instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Study NCT01144559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
Study NCT01144559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus Administered
Description: Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
Study NCT03516370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharomyces Boulardii 250 MG
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Study NCT03516370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Study NCT01223274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP
Description: Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
Study NCT01223274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard management practices
Description: Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
Study NCT03676569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADRC transplantation in autoimmune refractory epilepsy
Study NCT04195919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Participants receive Single oral administration of Evogliptin 5mg on day1
Study NCT04195919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period
Study NCT01331499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar Sealer (Aquamantys)
Description: Standard of care blood sparing techniques along with the use of bipolar sealer
Study NCT01331499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care blood sparing techniques without the useof bipolar sealer
Study NCT02994407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months.
Study NCT00777894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.